124 related articles for article (PubMed ID: 38018837)
1. Impact of antihistamine use on the survival outcomes of immune checkpoint inhibitors in advanced cancer patients.
Eylemer Mocan E; Yekedüz E; Karataş G; Yazgan SC; Köksoy EB; Çay Şenler F; Utkan G; Demirkazik A; Akbulut H; Ürün Y
Anticancer Drugs; 2024 Feb; 35(2):190-194. PubMed ID: 38018837
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of cationic amphiphilic antihistamines on outcomes of patients treated with immune checkpoint inhibitors.
Chiang CH; Chiang CH; Peng CY; Hsia YP; See XY; Horng CS; Chang YC; Shen XE; Wang SS; Tsai TC; Chen YJ; Ma KS; Chen BS; Luan YZ; Tay ST; Shen CH; Chung KC; Chiang CH; Peng CM
Eur J Cancer; 2022 Oct; 174():1-9. PubMed ID: 35964360
[TBL] [Abstract][Full Text] [Related]
3. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ
JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis.
Tian BW; Han CL; Wang HC; Yan LJ; Ding ZN; Liu H; Mao XC; Tian JC; Xue JS; Yang LS; Tan SY; Dong ZR; Yan YC; Wang DX; Li T
Clin Exp Metastasis; 2023 Aug; 40(4):255-287. PubMed ID: 37308706
[TBL] [Abstract][Full Text] [Related]
7. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
[TBL] [Abstract][Full Text] [Related]
8. Chronic hyperglycemia based on diabetes is independently associated with decreased survival in patients with advanced cancer treated with immune checkpoint inhibitors.
Yekedüz E; Köksoy EB; Yazgan SC; Karataş G; Şenler FÇ; Utkan G; Akbulut H; Demirkazik A; Ürün Y
Anticancer Drugs; 2022 Nov; 33(10):1145-1149. PubMed ID: 35946564
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of immune checkpoint inhibitors in advanced
Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
Front Immunol; 2022; 13():975246. PubMed ID: 36159795
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
11. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
[TBL] [Abstract][Full Text] [Related]
12. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts.
Wu Q; Liu J; Wu S; Xie X
Int Immunopharmacol; 2021 Mar; 92():107303. PubMed ID: 33465728
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
Wang R; Lin N; Mao B; Wu Q
J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
[TBL] [Abstract][Full Text] [Related]
14. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
Kim H; Kim DW; Kim M; Lee Y; Ahn HK; Cho JH; Kim IH; Lee YG; Shin SH; Park SE; Jung J; Kang EJ; Ahn MJ
Cancer; 2022 Feb; 128(4):778-787. PubMed ID: 34705268
[TBL] [Abstract][Full Text] [Related]
16. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G
Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effects of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with lung cancer and brain metastases: a propensity score-matched analysis.
Yomo S; Oda K; Oguchi K
J Neurosurg; 2023 Dec; 139(6):1628-1637. PubMed ID: 37243558
[TBL] [Abstract][Full Text] [Related]
19. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
Front Immunol; 2021; 12():651086. PubMed ID: 34248939
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.
Si J; Hao Y; Wei J; Xiang J; Xu C; Shen Q; Song Z
BMC Pulm Med; 2023 May; 23(1):158. PubMed ID: 37147602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]